NCT02535221 is a Phase 3 clinical trial of Goserelin+TAM+AI in Breast Cancer, sponsored by Peking University.

Who is sponsoring NCT02535221?

NCT02535221 is sponsored by Peking University.

What drugs are being tested in NCT02535221?

Interventions in NCT02535221: Goserelin+TAM+AI, Epirubicin+CTX+5-Fu.

What condition does NCT02535221 study?

NCT02535221 studies Breast Cancer.

Is NCT02535221 still recruiting?

NCT02535221 is currently recruiting now. Last updated 29 November 2021.

Last reviewed 2021-11-29 · How we verify

NCT02535221

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neoadjuvant Endocrine Therapy Versus Chemotherapy in Premenopausal Patients With ER+ & HER2- Breast Cancer

Recruiting now Phase 3 Last updated 29 November 2021

What this trial tests

Phase 3 trial testing Goserelin+TAM+AI in Breast Cancer in 234 participants. Currently enrolling.

Timeline

29 July 2015

Primary endpoint
30 June 2026

31 December 2026

Quick facts

Lead sponsor	Peking University
Phase	Phase 3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	234
Start date	29 July 2015
Primary completion	30 June 2026
Estimated completion	31 December 2026
Sites	1 location across China

Drugs / interventions tested

Goserelin+TAM+AI — full drug profile →
Epirubicin+CTX+5-Fu — full drug profile →

Conditions studied

Breast Cancer — all drugs for Breast Cancer →

Sponsor

Peking University

Who can join

Adults 35 to 55, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study proposes to prove that the efficacy of adjuvant endocrine therapy for the premenopausal HR positive breast cancer patients is non-inferiority to adjuvant chemotherapy assessed by ultrasound response rate.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

The Present and Future of Neoadjuvant Endocrine Therapy for Breast Cancer Treatment.
Martí C, Sánchez-Méndez JI. · · 2021 · cited 13× · PMID 34064183 · DOI 10.3390/cancers13112538
A Non-Inferior Randomized Trial of Neoadjuvant Endocrine Therapy Compared to Neoadjuvant Chemotherapy in Premenopausal Patients With Hormone-Responsive and HER2-Negative Lymph Node-Negative Breast Cancer.
Gu C, He Y, Zhang N, Liu Y, et al · · 2025 · PMID 40331570 · DOI 10.1177/10732748251339958

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other Peking University trials

Trials by the same sponsor.

NCT07519122 — Fangshan Active Nutrition Initiative · NA · not yet recruiting
NCT07466238 — HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer · NA · recruiting
NCT07480525 — Efficacy and Mechanisms of Escitalopram in Drug-Naïve First-Episode Major Depressive Disorder · NA · not yet recruiting
NCT07454031 — Intraperitoneal PX in Combination With Nab-Paclitaxel in Patients With Peritoneal Metastatic Mucinous Adenocarcinoma · Phase 1 · not yet recruiting
NCT07466225 — HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary Invasion · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02535221 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking University
Last refreshed: 29 November 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02535221.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing